Ken Griffin Revance Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$2.57 - $2.57 $33,924 - $33,924	13,200 Added 22.41%	72,100 $185,000
Q2 2024 Aug 14, 2024	SELL	$2.34 - $4.73 $93,132 - $188,254	-39,800 Reduced 40.32%	58,900 $151,000
Q1 2024 May 15, 2024	SELL	$4.65 - $9.31 $320,850 - $642,390	-69,000 Reduced 41.14%	98,700 $485,000
Q4 2023 Feb 14, 2024	BUY	$5.81 - $11.2 $220,779 - $425,600	38,000 Added 29.3%	167,700 $1.47 Million
Q3 2023 Nov 14, 2023	BUY	$11.47 - $25.07 $95,201 - $208,081	8,300 Added 6.84%	129,700 $1.49 Million
Q2 2023 Aug 14, 2023	SELL	$24.7 - $37.61 $526,110 - $801,093	-21,300 Reduced 14.93%	121,400 $3.07 Million
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $132,192 - $253,944	7,200 Added 5.31%	142,700 $4.6 Million
Q4 2022 Feb 14, 2023	SELL	$18.32 - $30.66 $5.69 Million - $9.52 Million	-310,600 Reduced 69.63%	135,500 $2.5 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $5.27 Million - $10.5 Million	368,000 Added 471.19%	446,100 $12 Million

233

82.1M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.